The National Pharmaceutical Pricing Authority (NPPA) has sent a notice to Cipla for allegedly overcharging customers. The government arm has imposed a fine on the company for selling Ciprofloxacin and Doxycycline medicines at a higher price than the one stated by the government.
NPPA is an agency established to fix the prices of controlled bulk drugs.
NPPA has asked the company to pay Rs 20.1 crore for Ciprofloxacin, this includes an amount of Rs 8.6 crore as interest charges, Cipla said in a statement to the Bombay Stock Exchange (BSE).
Cipla said it has also been asked to pay Rs 1.1 lakh for Doxycycline. The period, for which these amounts pertain to, has not been specified in the demand notice, the company said.
"These demands are contrary to the orders of the Supreme Court and the company has received legal advice that entire amounts demanded by the government are not tenable and sustainable," the company notification said.
Shares of the company settled at Rs 351.50, down 1.99 per cent on the BSE today.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app